Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Meghan Mullooly, Archbow Consulting’s Vice President, outlines the various types of available digital solutions when delivering patient services, while also sharing ways to drive efficiencies.  

Further Developing Patient Services 

Articles

The unveiling of the microbial fermentation manufacturing plant is headlined by a $131 million financial commitment.   

Fujifilm Opens Billingham Production Facility

In the final part of his Pharma Commerce video interview, Matt Hawkins, CaryHealth’s Chief Technology Officer, comments on the importance of mitigating security risks, along with ways to take action. 

An Extra Layer of Transparency and Accountability

Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.

Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine

A secret shopper survey study investigates how an FDA approval impacts patient access to a medication used to combat drug opioid overdose. 

The Cost and Availability of Naloxone Pre- and Post-OTC Authorization

In this part of his Pharma Commerce video interview, Matt Hawkins, CaryHealth’s Chief Technology Officer, explains the value of AI in the pharmacy environment. 

Utilizing Artificial Intelligence Behind the Counter

The 86,000 square-foot Køge facility will be fully functional by 2027. 

Novo Financially Commits $220 Million Toward New Plant in Denmark

In an interview with Pharma Commerce Editor Nicholas Saraceno, Matt Hawkins, CaryHealth’s Chief Technology Officer, describes how artificial intelligence can not only diagnose patients, but also deliver accurate medical advice.

Leveraging AI for the Benefit of Patients

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Medicare Unveils Results of First-Round Drug Price Negotiations

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’  Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

News